INSIGHT-IBD Pragmatic Study
INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab
The goal of this study is to evaluate the real-world effectiveness of treatments for inflammatory bowel disease (IBD) within routine clinical practice.
The study population includes adult patients (≥21 years) with ulcerative colitis (UC) or Crohn's disease (CD) receiving care in community gastroenterology practices in the United States.
The main questions it aims to answer are:
- Does treatment with mirikizumab reduce the proportion of patients requiring an increase in IBD disease management (e.g., unplanned visits, dose escalation, therapy switch, emergency department visits, or hospitalization)?
- Does treatment with mirikizumab improve clinical outcomes, including disease activity, clinical remission, and patient-reported outcomes, compared to standard biologic therapy?
- Researchers will compare patients treated with mirikizumab within the IBD Clinical Care Pathway versus patients receiving standard biologic therapies to see if mirikizumab leads to improved disease control and reduced healthcare utilization.
Participants will:
- Receive either mirikizumab or standard biologic therapy as part of routine clinical care
- Attend follow-up visits at approximately 3, 6, 12, and 18 months
- Have clinical data collected from electronic health records and healthcare utilization sources
- Complete patient-reported outcome questionnaires assessing symptoms, quality of life, and daily functioning
- Undergo routine laboratory tests and clinical assessments as part of standard care
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Lorraine O'Donnell
- Numero di telefono: 914-388-4907
- Email: lorraine.odonnell@cardinalhealth.com
Backup dei contatti dello studio
- Nome: Jessica Manzyuk
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age ≥21 years at the time of enrollment
- Confirmed diagnosis of ulcerative colitis (UC) or Crohn's disease (CD)
- Eligible for treatment with biologic therapy for IBD, defined as failure of prior conventional therapy and/or prior biologic therapy (excluding IL-23p19 antagonists)
- No prior exposure to mirikizumab and no contraindications to mirikizumab
- Ability to provide informed consent
- Willingness to comply with study procedures and follow-up requirements
Exclusion Criteria:
- Prior exposure to IL-23p19 antagonists (e.g., mirikizumab, risankizumab, guselkumab)
- Prior exposure to small molecule targeted therapies for IBD (e.g., JAK inhibitors or S1P receptor modulators)
- Participation in an interventional clinical trial within 90 days prior to enrollment
- History of extensive colorectal resection, including:
- Total proctocolectomy (for UC), or
- Surgical removal of two or more intestinal segments (for CD)
- Any condition that, in the investigator's judgment, may compromise patient safety, data integrity, or ability to participate in the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Mirikizumab Clinical Care Pathway
Participants receive mirikizumab as part of the IBD Clinical Care Pathway in routine clinical practice.
Dosing and administration follow the approved prescribing information for ulcerative colitis or Crohn's disease, with treatment and monitoring per standard of care.
|
Mirikizumab administered according to approved dosing regimens for ulcerative colitis and Crohn's disease.
|
|
Comparatore attivo: Standard Biologic Therapy Clinical Care Pathway
Participants receive standard biologic therapies for IBD as part of the IBD Clinical Care Pathway according to physician discretion and routine clinical practice.
Therapies may include anti-TNF agents, anti-integrins, IL-12/23 antagonists, or IL-23p19 antagonists.
|
Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.
Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.
Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.
Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of Patients Requiring an Increase in IBD Disease Management
Lasso di tempo: Up to 18 months following initiation of therapy
|
The proportion of patients requiring an increase in inflammatory bowel disease (IBD) disease management, defined as a composite of treatment and healthcare resource use, while receiving index therapy.
|
Up to 18 months following initiation of therapy
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Disease Activity Measured by Crohn's Disease PRO2 Scores
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Change from baseline in disease activity assessed using validated patient-reported outcome measures: Crohn's Disease Patient-Reported Outcome 2 (CD PRO2), composed of: Abdominal pain score (range 0-3) Stool frequency (number of bowel movements per day; higher values indicate worse disease activity) Changes in PRO2 component scores and composite disease activity will be evaluated over time, with decreases from baseline indicating improvement in disease activity. |
Baseline, 6 months, 12 months, and 18 months
|
|
Change in Disease Activity Measured by Ulcerative Colitis PRO2 Scores
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Change from baseline in disease activity assessed using validated patient-reported outcome measures: Ulcerative Colitis Patient-Reported Outcome 2 (UC PRO2), composed of: Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Total possible combined score range: 0-6, with higher scores indicating worse disease activity Changes in PRO2 component scores and composite disease activity will be evaluated over time, with decreases from baseline indicating improvement in disease activity. |
Baseline, 6 months, 12 months, and 18 months
|
|
Proportion of Participants Achieving Endoscopic Remission Measured by Simple Endoscopic Score for Crohn's Disease (SES-CD)
Lasso di tempo: Up to 18 months (as available from routine clinical care)
|
Proportion of participants achieving endoscopic remission assessed using validated endoscopic scoring system: Simple Endoscopic Score for Crohn's Disease (SES-CD) (range 0-56), where lower scores indicate less endoscopic disease activity and endoscopic remission is defined as a score ≤2 Endoscopic findings are collected as part of routine clinical care, when available. |
Up to 18 months (as available from routine clinical care)
|
|
Proportion of Participants Achieving Endoscopic Remission Measured by Modified Baron Score.
Lasso di tempo: Up to 18 months (as available from routine clinical care)
|
Proportion of participants achieving endoscopic remission assessed using validated endoscopic scoring systems: Modified Baron Score (ulcerative colitis) (range 0-4), where lower scores indicate less mucosal inflammation and endoscopic remission is defined as a score of 0 (normal mucosa with no visible inflammation) Endoscopic findings are collected as part of routine clinical care, when available. |
Up to 18 months (as available from routine clinical care)
|
|
Treatment Persistence
Lasso di tempo: Up to 18 months
|
Duration of time from treatment initiation to discontinuation of index therapy for any reason, including continued use at pre-specified timepoints.
|
Up to 18 months
|
|
Proportion of Patients with Dose Escalation
Lasso di tempo: Up to 18 months
|
Proportion of patients who discontinue index therapy and/or initiate a subsequent IBD therapy during the study period.
|
Up to 18 months
|
|
Time to Next Treatment
Lasso di tempo: Up to 18 months
|
Time from initiation of index therapy to initiation of a subsequent therapy or discontinuation of index therapy.
|
Up to 18 months
|
|
Concomitant Medication Use
Lasso di tempo: Baseline through 18 months
|
Proportion of patients receiving concomitant corticosteroids, immunomodulators, or aminosalicylates at baseline and during follow-up, including initiation and discontinuation patterns.
|
Baseline through 18 months
|
|
Corticosteroid-Free Time
Lasso di tempo: Up to 18 months
|
Duration of time patients remain free from corticosteroid use while receiving index therapy.
|
Up to 18 months
|
|
Healthcare Resource Utilization
Lasso di tempo: Up to 18 months
|
Frequency and rate of IBD-related healthcare utilization
|
Up to 18 months
|
|
Change in Patient-Reported Outcomes Measured by SIBDQ
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Change from baseline in patient-reported outcomes assessed using validated instrument: Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (range 10-70), where higher scores indicate better health-related quality of life Changes in scores over time will be evaluated to assess symptom burden, quality of life, and functional outcomes. |
Baseline, 6 months, 12 months, and 18 months
|
|
Change in Patient-Reported Outcomes Measured by UNRS
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Change from baseline in patient-reported outcomes assessed using validated instrument: Bowel Urgency Numeric Rating Scale (UNRS) (range 0-10), where higher scores indicate worse bowel urgency Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes. |
Baseline, 6 months, 12 months, and 18 months
|
|
Change in Patient-Reported Outcomes Measured by PROMIS Global Health
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Change from baseline in patient-reported outcomes assessed using validated instrument: PROMIS Global Health (PROMIS-GH) (T-score standardized, mean 50), where higher scores indicate better overall health status Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes. |
Baseline, 6 months, 12 months, and 18 months
|
|
Change in Patient-Reported Outcomes Measured by SAA
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Change from baseline in patient-reported outcomes assessed using validated instrument: Sexual Activity Avoidance (SAA), where higher scores indicate greater avoidance of sexual activity Changes in scores over time will be evaluated to assess symptom burden, quality of life, and functional outcomes. |
Baseline, 6 months, 12 months, and 18 months
|
|
Change in Patient-Reported Outcomes Measured by WPAI:SHP
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Change from baseline in patient-reported outcomes assessed using validated instrumens: Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) (0-100%), where higher percentages indicate greater impairment Changes in score over time will be evaluated to assess symptom burden, quality of life, and functional outcomes. |
Baseline, 6 months, 12 months, and 18 months
|
|
Proportion of Participants Achieving Clinical Remission Based on Ulcerative Colitis PRO2.
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Proportion of participants achieving clinical remission based on validated patient-reported outcome measures: Ulcerative Colitis Patient-Reported Outcome 2 (UC PRO2), composed of: Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Lower scores indicate less disease activity; clinical remission is defined as rectal bleeding score = 0 and stool frequency score ≤1 These thresholds represent minimal or no symptoms consistent with clinical remission. |
Baseline, 6 months, 12 months, and 18 months
|
|
Proportion of Participants Achieving Clinical Remission Based on Crohn's Disease PRO2.
Lasso di tempo: Baseline, 6 months, 12 months, and 18 months
|
Proportion of participants achieving clinical remission based on validated patient-reported outcome measures: Crohn's Disease Patient-Reported Outcome 2 (UC PRO2), composed of: Stool frequency score (range 0-3) Rectal bleeding score (range 0-3) Lower scores indicate less disease activity; clinical remission is defined as rectal bleeding score = 0 and stool frequency score ≤1 These thresholds represent minimal or no symptoms consistent with clinical remission.
|
Baseline, 6 months, 12 months, and 18 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Casey Chapman, MD, GIA
- Investigatore principale: Nicholas Lazarou, MPH, MBA, Cardinal Health
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie intestinali
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie del colon
- Gastroenterite
- Malattie infiammatorie intestinali
- Colite
- Colite, ulcerosa
- Malattia di Crohn
- Peptidi
- Aminoacidi, peptidi e proteine
- Proteine
- Fattori biologici
- Peptidi e proteine di segnalazione intercellulare
- Citochine
- Interleuchi
- Interleuchina-12
- Interleuchina-23
- Mirikizumab
Altri numeri di identificazione dello studio
- 103899
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Malattia di Crohn (CD)
-
Shandong UniversityAttivo, non reclutanteMalattia di Crohn (CD)Cina
-
Asian Institute of Gastroenterology, IndiaReclutamentoMalattia di Crohn (CD) | Morbo di Crohn perianaleIndia
-
Shmuel Kivity, MDReclutamento
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...ReclutamentoMalattia di Crohn (CD) | IntensificationFrancia
-
University of GlasgowNHS Lothian; NHS Tayside; NHS Grampian; NHS Lanarkshire; NHS Greater Clyde and Glasgow e altri collaboratoriReclutamentoMalattia di Crohn (CD)Regno Unito
-
University Hospital, Clermont-FerrandNon ancora reclutamento
-
Central Hospital, Nancy, FranceNon ancora reclutamentoMalattia di Crohn (CD)Francia
-
GLSMED Learning Health S.A.Non ancora reclutamento
-
University Hospital, Clermont-FerrandAttivo, non reclutanteMalattia di Crohn (CD)Francia
-
Mak Wing YanNon ancora reclutamentoMalattia di Crohn (CD)Hong Kong
Prove cliniche su Mirikizumab
-
Eli Lilly and CompanyReclutamentoMalattia di Crohn | Colite, ulcerosaIsraele, Belgio, Ungheria, Stati Uniti, Italia, Cina, Germania, Polonia, Brasile, Canada
-
Eli Lilly and CompanyReclutamentoMalattia di CrohnIsraele, Belgio, Ungheria, Stati Uniti, Italia, Cina, Germania, Polonia, Brasile, Canada
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...ReclutamentoMalattia di Crohn (CD)Francia
-
Eli Lilly and CompanyNon ancora reclutamentoMalattia infiammatoria intestinale | AllattamentoStati Uniti, Spagna, Danimarca, Israele, Italia, Germania, Polonia, Canada
-
Eli Lilly and CompanyReclutamento
-
Eli Lilly and CompanyCompletatoColite ulcerosaStati Uniti, Belgio, Francia, Germania, Polonia, Giappone, Israele, Italia, Regno Unito, Canada, Corea del Sud
-
University of North Carolina, Chapel HillEli Lilly and CompanyReclutamentoPouchite | Borsa, Ileal | Sacchetti, IleoanalStati Uniti
-
Eli Lilly and CompanyCompletato
-
Eli Lilly and CompanyCompletatoColite ulcerosaSpagna, Stati Uniti, Cina, Australia, Austria, Giappone, Ungheria, Taiwan, Canada, Italia, Belgio, Polonia, Svizzera, India, Israele, Ucraina, Danimarca, Messico, Romania, Malaysia, Argentina, Cechia, Francia, Germania, Irlanda, Let... e altro ancora
-
Eli Lilly and CompanyCompletato